Skip Navigation


JAC Advance Access originally published online on June 11, 2009
Journal of Antimicrobial Chemotherapy 2009 64(2):259-262; doi:10.1093/jac/dkp204
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/2/259    most recent
dkp204v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hauck, Y.
Right arrow Articles by Pourcel, C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hauck, Y.
Right arrow Articles by Pourcel, C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Original research

Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin

Yolande Hauck1, Michel Fabre2, Gilles Vergnaud1, Charles Soler2 and Christine Pourcel1,*

1 Université Paris-Sud 11, Institut de Génétique et Microbiologie, CNRS, UMR8621, 91405 Orsay, France 2 Laboratoire de mycobactériologie, HIA Percy, 101 avenue Henri Barbusse, 92140 Clamart, France

Received 13 October 2008; returned 27 January 2009; revised 4 May 2009; accepted 12 May 2009

* Corresponding author. Tel: +33-1-69-15-30-01; Fax: +33-1-69-15-66-78; E-mail: christine.pourcel{at}u-psud.fr

Objectives: The aim of this study was to compare the efficiency of two commercial assays, INNO-LiPA Rif.TB and MTBDRplus, for the identification of mutations in the rpoB hot-spot region and to assess the efficiency of these mutations in conferring resistance to rifampicin.

Methods: A collection of 126 rifampicin-resistant Mycobacterium tuberculosis and Mycobacterium africanum isolates and 18 rifampicin-susceptible isolates from different countries were analysed using the two hybridization assays.

Results: For 60 strains the hot-spot region of the rpoB gene was sequenced, confirming the results of the hybridization assays and allowing the identification of new mutations. In total, 17 mutations involving 10 codons were observed, two of which are newly described (D516Y and E562G/P564L). Mutations L533P, H526L, D516Y and L511P and the double mutation E562G/P564L conferred a low level of resistance.

Conclusions: The assays INNO-LiPA Rif.TB and MTBDRplus identified rpoB mutations in 98.4% of cases. MTBDRplus provided additional information due to the overlapping hybridization probes and in addition allowed the investigation of katG mutations for isoniazid resistance.

Keywords: antibiotics , M. tuberculosis , hybridization , probes , rifabutin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.